Puma Cuts Royalty Guidance as Generics Gain China
The biotech reported $55.1 million in third-quarter revenue and became debt-free after its final loan payment.
Updated on Nov. 8, 2026 in Biotech
Puma Biotechnology reported total revenue of $55.1 million for the third quarter of 2026. The company lowered full-year royalty guidance to $18 million to $19 million after generic versions of NERLYNX gained market share in China.
Why it matters
A lower contractual royalty rate takes effect once generic NERLYNX gains share in China, reducing Puma's royalty income from that market. The change comes as the company works toward positive net income in 2026.
Puma recorded a $2.1 million cumulative reduction to Q3 2026 royalty revenue, and its $108.5 million in cash and marketable securities follows a final $11.1 million principal payment to Athyrium. The filing does not specify the full extent of royalty erosion from generic competition in China beyond the revised guidance.
The players
Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company that markets the breast cancer drug NERLYNX and earns royalties on its sales.
The details
Generic NERLYNX competitors gained share in China, triggering a contractual lower royalty rate that Puma applied to its third-quarter results. Puma received third-party market data in October 2026 showing generic market share reached a threshold during 2025.
Timeline
Q2 2026: Puma made its final principal loan payment and became debt-free.
2025: Generic NERLYNX share in China reached the threshold triggering the lower royalty rate.
October 2026: Puma received third-party generic NERLYNX market data.
Nov. 5, 2026: Puma held its third-quarter 2026 earnings call.
Market Landscape
Generic NERLYNX competitors in China have reduced the royalty rate Puma earns there, even as U.S. demand for the drug heads toward a second consecutive year of growth. The divergence between the two markets shapes how Puma's royalty income is set for the coming year.
For patients and investors tracking Puma, the lower royalty guidance signals reduced income from China as generic NERLYNX takes share there. The company's debt-free status and $108.5 million cash position give it room to fund its planned phase III work.
The takeaway
Generic competition can reset a royalty-based biotech's income in a single market even while demand grows elsewhere. Watch whether Puma's U.S. NERLYNX growth offsets China erosion in its next guidance update.
What happens next
Management plans to engage global health regulators in the first half of 2027 to design a pivotal phase III study of alisertib.
Further reading
For more on the companies developing these treatments, explore the Biotech section.
Source note: This article includes information reported by The Motley Fool.
